diabetes mellitus
Conditions
Interventions
Group B:Metformin+Acarbose Tablets
Group C:Metformin+Saxagliptin
Group D:Metformin+Dapagliflozin
Sponsors
Affiliated Hospital of Weifang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. informed consents be given before treatment; 2. the newly-diagnosed type 2 diabetic patients; 3. fasting blood glucose (FBG) level ranging from 7.0-16.7 mmol/L; 4. aged 18 to 75 years old; 5. never be treated with any anti-hyperglycemic agents
Exclusion criteria
Exclusion criteria: 1. having any severe acute or chronic complications; 2. renal dysfunction, blood creatinine=150µmol/L; 3. blood aminotransferase level rising up(more than 2 times of the normal level); 4. any severe cardiac disease including congestive cardiac failure, unstable angina and myocardial infarct in 12 months; 5. serious hypertension (systolic pressure=180mmHg and/ or diastolic pressure=110mmHg); 6. chronic or acute pancreatic disease; 7. severe systematic diseases or malignant tumor; 8. allergic to the drugs using in the trial; 9. any factors interfering the result; 10. female patients incline to be pregnant; 11. being treated with corticosteroid, immunosuppressing drugs or cytotoxic drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting plasma glucose;2-hours postprandial plasma glucose;fasting C-peptide;Fasting insulin;Insulin resistance index;Insulin secretion index;glycated hemoglobin A1c; | — |
Secondary
| Measure | Time frame |
|---|---|
| body mass index;Hypoglycemia Incidence;Adverse Event; | — |
Countries
China
Contacts
Public ContactSun Xiaodong
Affiliated Hospital of Weifang Medical University
Outcome results
None listed